Quadruple immunotherapy will promise excellent graft survival in cadaveric renal transplants using cardiac arrest donor grafts.
Hoshinaga
K
K
Department of Urology, Fujita Health University, School of Medicine, Aichi, Japan.
Shiroki
R
R
Higuchi
T
T
Horiba
Y
Y
Yanaoka
M
M
Naide
Y
Y
D000293:Adolescent; D000328:Adult; D000961:Antilymphocyte Serum / Q000627:therapeutic use; D001379:Azathioprine / Q000627:therapeutic use*; D002102:Cadaver; D003404:Creatinine / Q000097:blood; D016572:Cyclosporine / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005500:Follow-Up Studies; D006085:Graft Survival; D006323:Heart Arrest; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000276:immunology* / Q000401:mortality / Q000502:physiology; D008775:Methylprednisolone / Q000627:therapeutic use*; D008875:Middle Aged; D012263:Ribonucleosides / Q000627:therapeutic use*; D015996:Survival Rate; D014019:Tissue Donors
D000961:Antilymphocyte Serum; D007166:Immunosuppressive Agents; D012263:Ribonucleosides; C010052:mizoribine; D016572:Cyclosporine; D003404:Creatinine; D001379:Azathioprine; D008775:Methylprednisolone